Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 14/20 | 0.61 |
| ▸ | CRBN | Q96SW2 | 14/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23538836 | 0.94 | DDB1 (0.68) | DDB1CRBNDRD2DRD4DRD3 | |
| SCHEMBL23301404 | 0.94 | DDB1 (0.68) | DDB1CRBNDRD2DRD4DRD3 | |
| Trifluoroacetic Acid SCHEMBL25167571 | 0.86 | DDB1 (0.48) | DDB1CRBNS1PR1 | |
| Trifluoroacetic Acid SCHEMBL25169720 | 0.86 | DDB1 (0.48) | DDB1CRBNS1PR1 | |
| SCHEMBL29744852 | 0.82 | DDB1 (0.64) | DDB1CRBNDRD2DRD4DRD3 | |
| SCHEMBL23551746 | 0.82 | DDB1 (0.64) | DDB1CRBNDRD2DRD4DRD3 | |
| SCHEMBL23301551 | 0.82 | DDB1 (0.64) | DDB1CRBNDRD2DRD4DRD3 | |
| SCHEMBL23538927 | 0.80 | DDB1 (0.72) | DDB1CRBN | |
| SCHEMBL24124617 | 0.79 | DDB1 (0.54) | DDB1CRBNS1PR1 | |
| SCHEMBL25167579 | 0.79 | DDB1 (0.54) | DDB1CRBNS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230024096-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | C4 THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024096-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | SMARCC1, SMARCC2, SMARCA2 | DDB1 415/4885CRBN 358/4885DRD2 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.